DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas
DNMT1 is a target of approved anti-cancer drugs including decitabine. However, the prognostic value of DNMT1 protein expression in R-CHOP-treated diffuse large B-cell lymphomas (DLBCLs) remains unexplored. Here we showed that DNMT1 was expressed in the majority of DLBCL cases (n = 209/230, 90.9%) wi...
Main Authors: | Loo, SK, Ch'ng, ES, Lawrie, CH, Muruzabal, MA, Gaafar, A, Pomposo, MP, Husin, A, Salleh, MS, Banham, AH, Pedersen, LM, Møller, MB, Green, TM, Wong, KK |
---|---|
Format: | Journal article |
Published: |
Elsevier
2017
|
Similar Items
-
Roles of Ki67 in Breast Cancer - Important for Management?
by: Yip, C.H., et al.
Published: (2016) -
To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
by: Francesca Di Rosa, et al.
Published: (2021-04-01) -
The intrinsically disorderly story of Ki-67
by: Lucy Remnant, et al.
Published: (2021-08-01) -
Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia
by: Kah Keng Wong, et al.
Published: (2019-05-01) -
Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
by: Gasperetti F, et al.
Published: (2011-03-01)